PMD-200™ and the NOL® index are commercially available in Australia!
We are happy to share with you the Medasense received approval to market the PMD-200™ system in Australia.
The PMD-200™ and its NOL® index are currently commercially available in
NOL® is now officially a registered trademark!
We are proud to share with you that the trademark “NOL NOCICEPTION LEVEL INDEX” is approved and registered as Medasense’s trademark in the Europe and in the US!
Medasense won the 2017 CEWIT Startup Contest
Medasense won the 2017 Center of Excellence in Wireless and Information Technology (CEWIT) Startup Contest at State University of New York, Stonybrook!
cewit.org/conference2017
Medasense featured at the British Journal of Anaesthesia (BJA)
We are excited to share that Medasense’s technology was chosen to be highlighted in the British Journal of Anaesthesia (BJA) review article “Digital innovations and emerging technologies for enhanced recovery programmes”.
Receipt of Israeli AMAR
We are pleased to share with you the exciting news that Medasense has received AMAR approval to sell our pain (Nociception) monitoring system in Israel!
Israeli anesthesiologists are now able to join their European colleagues, who are
Does that hurt??
Medasense featured in Innovations in Pharmaceutical Technology publication.
Read our article written by CEO, Galit Zuckerman-Stark, to learn how an objective approach could help healthcare professionals better assess pain.
Article in Anesthesiology News
Medasense headlines “Anesthesiology News” – the most-read publication by anesthesiologists in the USA!!
The article reports on clinical trial results previously published in Anesthesiology in 2016, with insightful interviews from lead investigators, Dr. Daniel Sessler (Head of Center of Outcomes Research, Cleveland Clinic, Ohio, USA) and Dr. Ruth Edry (Department of Anesthesiology, Rambam Medical Centre, Haifa, Israel).